ArticleBMC infectious diseases2026
Early laboratory-based differentiation of severe influenza pneumonia and influenza-associated encephalopathy in children using a multi-model, stability-aware machine-learning workflow: a single-center retrospective cohort study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundInfluenza-associated encephalopathy and acute necrotizing encephalopathy (ANE) are rare but devastating complications of pediatric influenza, and early differentiation from severe pneumonia without neurological involvement is challenging at admission. We aimed to develop and internally validate an early prediction model to distinguish severe influenza A pneumonia from influenza-associated central nervous system (CNS) involvement using routine admission laboratory tests. The intended clinical use is early triage: to prioritize neurological evaluation (e.g., EEG/neuroimaging when indicated), closer monitoring, and escalation of care for children predicted to be at higher risk of CNS involvement.
methodsIn this retrospective cohort at a tertiary pediatric center, consecutive children hospitalized with RT-PCR-confirmed influenza A from 1 January 2023 to 1 June 2025 were classified as mild pneumonia (Group 1), severe pneumonia without neurological involvement (Group 2), or CNS involvement (Group 3) using prespecified clinical, neurophysiological, and neuroimaging criteria. The primary prediction contrasted Group 2 versus Group 3 using routine laboratory tests obtained within 6 h of admission. Several machine-learning algorithms were trained and tuned using internal resampling and a held-out validation set. Bootstrap stability selection identified robust markers, and a parsimonious elastic-net logistic regression model was derived. We assessed discrimination, calibration, and clinical net benefit at prespecified risk thresholds (0.15, 0.25 and 0.35).
resultsAmong 227 eligible children (median age 4.2 years), 95 (41.9%) had mild pneumonia, 74 (32.6%) severe pneumonia without neurological involvement, and 58 (25.6%) influenza-associated CNS involvement; mortality was 0%, 4.1%, and 22.4%, respectively. In the primary task of distinguishing Group 2 from Group 3 using admission laboratory tests, the ten prespecified algorithms achieved out-of-fold AUCs of 0.77-0.90, and simple probability averaging achieved an AUC of 0.91. Stability selection identified 11 robust biochemical markers; a parsimonious elastic-net logistic regression model restricted to eight markers achieved a validation AUC of 0.89 with good calibration (Brier score 0.12) and consistently positive net benefit on decision-curve analysis across prespecified risk thresholds (0.15, 0.25, and 0.35).
conclusionsIn internal validation, an eight-marker model differentiated severe pneumonia without neurological involvement from influenza-associated CNS involvement with a validation AUC of 0.89 and good calibration. This stability-aware framework provides an implementable baseline for multicenter external validation and refinement, rather than a ready-to-use clinical tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.